This protocol covers the management of Ebola virus disease — whether suspected or confirmed — in patients who concurrently present with uncomplicated malaria, a clinically significant co-infection requiring targeted intervention within the EVD care setting.
Empiric antimalarial therapy should be administered to all febrile patients with suspect and confirmed EVD. The concurrent presence of uncomplicated malaria is a defining feature of this clinical scenario and directly informs the therapeutic approach.
An artemisinin-based combination antimalarial is central to this protocol — the specific agent selection and patient-level parameters are defined in the full structured regimen.
The primary clinical target is malaria testing turning negative, confirming parasitic clearance.